Pharmacopsychiatry 2004; 37(1): 12-17
DOI: 10.1055/s-2004-815469
Original Paper
© Georg Thieme Verlag Stuttgart · New York

Patterns of Antipsychotic Utilization in a Tertiary Care Psychiatric Institution

R. M. Procyshyn1 , 2 , B. Thompson3
  • 1Division of Research, Riverview Hospital, Port Coquitlam, BC, Canada
  • 2Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC, Canada
  • 3Department of Pharmacy, Riverview Hospital, Port Coquitlam, BC, Canada
This project was funded by an unrestricted education grant from Eli Lilly Canada
Further Information

Publication History

Received: 26.7.2002 Revised: 30.10.2002

Accepted: 28.11.2002

Publication Date:
29 January 2004 (online)

Objective: To perform a retrospective survey of discharge medications at a tertiary care psychiatric facility in an attempt to gain insight into, and perhaps an understanding of, the most recent pattern of antipsychotic utilization in patients with a diagnosis not restricted to schizophrenia.

Methods: This is a retrospective survey that used the Department of Pharmacy’s computer database to obtain relevant discharge information on all non-geriatric patients discharged from Riverview Hospital between 1 January and 31 December 2000. The records of 372 patients met the inclusion criteria and formed the database for the survey.

Results: The results of this survey revealed a relatively high prevalence of antipsychotic polypharmacy (the use of two antipsychotics). Perhaps surprisingly, the highest rate of antipsychotic polypharmacy was found in individuals diagnosed with schizoaffective disorder (49.3 %), followed by schizophrenia (44.7 %), bipolar disorder (29.9 %), and psychosis not otherwise specified (22.5 %).

Conclusion: Although antipsychotic polypharmacy is not a new phenomenon in schizophrenia, this study is the first to document its employment among other diagnoses.

References

  • 1 Bennett J L, Hamilton D L. Sequential use of antidepressant drugs with chlorpromazine in chronic schizophrenia.  Psychiatr Quart. 1963;  37 53-65
  • 2 Casey J F, Hollister L E, Klett J, Lasky J J, Caffey EM E M Jr. Combined drug therapy of chronic schizophrenics.  Am J Psychiat. 1961;  117 997-1003
  • 3 Clark A F, Holden N L. The persistence of prescribing habits: a survey and follow-up of prescribing to chronic hospital in-patients.  Br J Psychiat. 1987;  150 8-91
  • 4 Cooper J E. Schizophrenia and allied condition.  Med Int. 1991;  94 3917-3922
  • 5 Davies L O, Drummond M. The economic burden of schizophrenia.  Psychiatr Bull. 1990;  14 522-525
  • 6 Diamond H, Tislow R, Snyder T Jr, Rickles K. Peer review of prescribing patterns in a CHMC.  Am J Psychiat. 1976;  133 697-699
  • 7 Edwards S, Kumar V. A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital.  Br J Psychiat. 1984;  145 502-507
  • 8 Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine.  Biol Psychiat. 1997;  42 522-523
  • 9 Hemminki E. Polypharmacy among psychiatric patients.  Acta Psychiatric Scand. 1977;  56 347-356
  • 10 Henderson D C, Goff D C. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.  J Clin Psychiat. 1996;  57 395-397
  • 11 Kennedy N B, Procyshyn R M. Rational antipsychotic polypharmacy.  Can J Clin Pharmacol. 2000;  7 155-159
  • 12 Ketter T A, Winsberg M E, DeGolia S G. et al . Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states.  J Clin Psychiat. 1998;  59 83-85
  • 13 Leff J. Schizophrenia: etiology, prognosis and course. In: Jenkins R, Field V, Young R, editor The primary care of schizophrenia. London; HMSO Department of Health 1992
  • 14 McElroy S L, Frye M, Denicoff K. et al . Olanzapine in treatment-resistant bipolar disorder.  J Affect Disord. 1998;  49 119-122
  • 15 Michel K, Kolakowska T. A survey of prescribing psychotropic drugs in two psychiatric hospitals.  Br J Psychiat. 1981;  138 217-221
  • 16 Muijen M, Siverstone T. A. Comparative hospital survey of psychotropic drug prescribing.  Br J Psychiat. 1987;  50 510-514
  • 17 Procyshyn R M, Kennedy N. Theoretical basis for loxapine augmentation in risperidone partial responders.  Clin Drugs Invest. 2000;  9 257-266
  • 18 Procyshyn R M, Kennedy N B, Tse G, Thompson B. Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution.  Can J Psychiat. 2001;  46 334-339
  • 19 Ravindran A V, Jones B W, Al-Zaid K, Lapierre Y D. Effective treatment of mania with olanzapine: 2 case reports.  J Psychiat Neurosci. 1997;  22 345-346
  • 20 Schmidt L G, Lammers V, Stockel M, Muller-Oerlinghausen B. Recent trends in prescribing psychotropic drugs at a psychiatric university hospital (1981 - 84).  Pharmacopsychiatry. 1988;  21 126-130
  • 21 Schmidt L G, Niemeyer R, Muller-Oerlinghausen B. Drug prescribing pattern of a psychiatric university hospital in germany.  Pharmacopsychiatry. 1983;  16 35-42
  • 22 Sharma V, Pistor L. Treatment of bipolar mixed sate with olanzapine.  J Psychiat Neurosci. 1999;  24 40-44
  • 23 Sheppard C, Collins L, Fiorentino D, Fracchia J, Merlis S. Polypharmacy in psychiatric treatment: incidence at a state hospital.  Curr Therapeut Res. 1969;  11 765-774
  • 24 Shiloh R, Zemishlany D, Radwan A M. et al . Sulpriride augmentation in people with schizophrenia partially responsive to clozapine.  Br J Psychiat. 1997;  171 569-573
  • 25 Soutullo C A, Sorte M T, Foster K D, McElroy S L, Keck P E. Olanzapine in the treatment of adolescent acute mania: A report of seven cases.  J Affect Disord. 1999;  53 279-283
  • 26 Stahl S M. Antipsychotic polypharmacy, Part I: therapeutic option or dirty little secret?.  J Clin Psychiat. 1999;  60 425-426
  • 27 Talbot D R. Are tranquilizer combinations more effective than a single tranquilizer?.  Am J Psychiat. 1967;  117 997-1000
  • 28 Tohen M, Jacobs T G, Grundy S L. et al . Efficacy of olanzapine in acute bipolar mani.  Arch Gen Psychiat. 2000;  577 841-849
  • 29 Tohen M, Sanger T M, McElroy S L. et al . Olanzapine versus placebo in the treatment of acute mania.  Am J Psychiat. 1999;  156 702-709
  • 30 Viorol P, Rober P -A. Meister P, Oros L, Baumann P. Psychotropic drug prescription in a psychiatric university hospital.  Pharmacopsychiatry. 1999;  32 29-37
  • 31 Weisler R H, Ahearn E P, Davidson J R, Wallace C D. Adjunctive use of olanzapine in mood disorders: Five case reports.  Ann Clin Psychiat. 1997;  9 259-262
  • 32 Working Group for the Canadian Psychiatric Association and the Canadian Alliance for Research on S chizophrenia. Canadian clinical practice guidelines for the treatment of schizophrenia.  Can J Psychiat. 1998;  43[Suppl 2 revised] 1S-39S
  • 33 Yosselson-Superstine S, Sternik D, Liebenzon D. Prescribing patterns in psychiatric hospitals in Israel.  Acta Psychiatric Scand. 1979;  60 477-482
  • 34 Zullino D, Baumann P. Olanzapine for mixed episodes of bipolar disorder.  J Psychopharmacol. 1999;  13 198

Dr. Ric M. Procyshyn

422 Henry Esson Young Building

500 Lougheed Highway

Riverview Hospital

Port Coquitlam, British Columbia

Canada

V3C 4J2

Phone: (604) 524-7384

Fax: (604) 524-7693

Email: rprocyshyn@bcmhs.bc.ca